The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven’t responded to oral ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression.

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson's nasal spray, Spravato, to allow it to be used ...

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

The Food and Drug Administration on Tuesday approved Johnson & Johnson's nasal spray to be used alone in adults with a major ...

Rep. Mike Collins (R-Ga.) heavily criticized statements made by the Right Rev. Mariann Budde on Tuesday at the inaugural ...

Johnson & Johnson has announced that the U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

The TGA has issued a requirement for new warnings to be provided with the drug montelukast, commonly used to treat asthma and ...